Trevor Huber, DO
Family Medicine · Little Elm, TXNPI 1649682857
Payments from drug & device makers
Across 243 payments — averaging $14.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$761
- Novo Nordisk$445
- Lilly USA, LLC$270
- AstraZeneca$216
- Amgen$208
- Pfizer$170
- plus $2K from 24 others
What the payments were for
- Food & beverage$3,630100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 67 | $761 |
| Novo Nordisk | 40 | $445 |
| Lilly USA, LLC | 17 | $270 |
| AstraZeneca | 15 | $216 |
| Amgen | 13 | $208 |
| Pfizer | 10 | $170 |
| Otsuka America Pharmaceutical, Inc. | 7 | $168 |
| Biohaven Pharmaceuticals, Inc. | 6 | $142 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $124 |
| Abbott | 7 | $123 |
| Boehringer Ingelheim | 8 | $122 |
| Merck | 6 | $111 |
| Johnson & Johnson | 6 | $104 |
| Sanofi-aventis U.S. LLC | 6 | $99 |
| GSK | 4 | $90 |
| Eisai Inc. | 3 | $66 |
| Exact Sciences | 4 | $63 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Genentech USA, Inc. | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Corcept Therapeutics | 1 | $30 |
| Lundbeck LLC | 1 | $30 |
| Gilead | 1 | $26 |
| Assertio Therapeutics, Inc. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Novartis | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$3,630 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 85 | $138,079 |
| EliquisApixaban | 55 | $67,529 |
| FarxigaDapagliflozin Propanediol | 60 | $58,606 |
| MounjaroTirzepatide | 34 | $38,707 |
| JardianceEmpagliflozin | 16 | $21,674 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $21,587 |
| EntrestoSacubitril/Valsartan | 13 | $20,787 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $18,713 |
| XareltoRivaroxaban | 13 | $15,557 |
| Atorvastatin Calcium | 376 | $2,793 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $2,767 |
| Bupropion XlBupropion Hcl | 80 | $2,386 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,105 |
| Omeprazole | 77 | $1,427 |
| Gabapentin | 61 | $1,393 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $445 | $138,07985 claims |
| PfizerEliquis | $170 | $67,52955 claims |
| AstraZenecaFarxiga | $216 | $58,60660 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $90 | $40,30060 claims |
| Lilly USA, LLCMounjaro | $270 | $38,70734 claims |
| Boehringer IngelheimJardiance | $122 | $21,67416 claims |
| NovartisEntresto | $20 | $20,78713 claims |
| Johnson & JohnsonXarelto | $104 | $15,55713 claims |
| AbbVieSynthroid | $761 | $1,03211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Little Elm
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.